Could a common diabetes drug protect aging brains?

NCT ID NCT07395960

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether metformin, a diabetes drug, can improve memory and thinking in overweight adults aged 60-75 with mild cognitive impairment. Half of the 54 participants will take metformin daily for 26 weeks, while the other half will receive lifestyle advice only. Researchers will use brain scans and memory tests to see if metformin helps.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huadong Hospital, Fudan University

    RECRUITING

    Shanghai, 200040, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

metformin

What this could lead to

If it works, this could point toward a way to slow cognitive decline in elderly people who are overweight, potentially reducing dementia risk.

What could go wrong

This is a small, early-phase trial with only 54 people. Metformin has shown mixed results in past studies, and the improvement may be small or not happen at all.

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.